GORE® VIABAHN®
Endoprosthesis
with Heparin Bioactive Surface*

One-year findings from a prospective, real-world, multicenter study from Japan[1]

Outcomes after treatment of a stenosed or occluded venous anastomosis of a synthetic arteriovenous (AV) access graft.

Sustained secondary patency at the target lesion and access circuit



No statistical difference in repeat interventions at the target lesion with respect to[1]:

- Crossing the elbow
- Sex
- Number of prior interventions
- Diabetes
- Stent graft size and location
- Stenosis vs. occlusion
- Elephant trunk placement (stent graft in the outflow vein lies without vessel wall apposition)

* As used by Gore, Heparin Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.

Together, improving life

VIABAHN® Device

One-year primary patency[1]



Target lesion



Access circuit

65% **Target lesion primary patency**
in patients where the VIABAHN® Device was placed across the elbow (N = 9) with no reported fractures.

1. Fukasawa M, Haruguchi H. A 1-year follow-up analysis of a post market surveillance study of a self-expanding endoprosthesis for stenosis or occlusion at the arteriovenous access. Journal of Vascular Access. In press. OPEN ACCESS https://journals.sagepub.com/doi/10.1177/11297298251330951

Consult Instructions for Use
eifu.goremedical.com

INDICATIONS FOR USE IN THE U.S.: The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm. The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm. The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. **CONTRAINDICATIONS:** The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is contraindicated for non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system. Do not use the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ℞ Only

Products listed may not be available in all markets.

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc.
GORE, *Together, improving life,* VIABAHN and designs are trademarks of W. L. Gore & Associates.
© 2025 W. L. Gore & Associates, Inc. 25PL1022-EN01 MAY 2025

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771